Saturday 17 October 2026
Export DMAC’s income statement to Excel — free account
DiaMedica Therapeutics, Inc.
DMAC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 5.56%, free cash flow fell 6.75% and total debt fell 90.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.57
0.47
−5.85%
Follow DMAC
DiaMedica Therapeutics, Inc. (DMAC) P/E ratio
DiaMedica Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2018 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OVID Ovid Therapeutics compare | n/m |
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| PRTCY PureTech Health PLC Sponsored ADR compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| PROK ProKidney Corp. compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. | n/m |
| CAPR Capricor Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)